191 related articles for article (PubMed ID: 37286702)
21. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
22. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
24. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
25. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
26. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
27. m
Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
[TBL] [Abstract][Full Text] [Related]
28. The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Zhu C; Du Y; Huai Q; Fang N; Xu W; Yang J; Li X; Zhang Y; Zhang X; Dai H; Li X; Wang H; Dai Y
Reprod Sci; 2024 Feb; 31(2):532-549. PubMed ID: 37798609
[TBL] [Abstract][Full Text] [Related]
29. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
30. Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer.
Wang Y; Qu X; Li L; He D
Biomed Res Int; 2022; 2022():5432806. PubMed ID: 36262972
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
32. Identification of the prognostic value of a 2-gene signature of the WNT gene family in UCEC using bioinformatics and real-world data.
Hu Y; Zheng M; Zhang D; Gou R; Liu O; Wang S; Lin B
Cancer Cell Int; 2021 Sep; 21(1):516. PubMed ID: 34565373
[TBL] [Abstract][Full Text] [Related]
33. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of KIF23 as a hypoxia-regulated lactate metabolism-related oncogene in uterine corpus endometrial carcinoma.
Wang T; Peng X; Liu W; Ji M; Sun J
Life Sci; 2024 Mar; 341():122490. PubMed ID: 38336274
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
36. Development of a 4-miRNA prognostic signature for endometrial cancer.
Huang J; Du F; Wang N
Medicine (Baltimore); 2022 Oct; 101(41):e30974. PubMed ID: 36254064
[TBL] [Abstract][Full Text] [Related]
37. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
38. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
Xue S; Su XM; Ke LN; Huang YG
Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
[TBL] [Abstract][Full Text] [Related]
39. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
[TBL] [Abstract][Full Text] [Related]
40. Gene Signatures and Prognostic Value of m6A RNA Methylation Regulators in Uterine Corpus Endometrial Carcinoma.
Feng Y; Yao C; Shen J; Zhou J
Discov Med; 2021; 31(164):111-120. PubMed ID: 35188885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
